- Gross quarterly revenue of $7.1
million
- Fiscal Q2/24 marks tenth consecutive quarter generating
positive net income
- Adjusted EBITDA1 in fiscal Q2/24 of $0.6 million
- Over 2000% growth in net revenue from Cultivation &
Wholesale segment
CALGARY,
AB, April 1, 2024 /CNW/ - CanadaBis
Capital Inc. (the "Company" or "CanadaBis") (TSXV: CANB), a premium
vertically integrated Canadian cannabis company, is pleased to
announce results from our second quarter fiscal 2024, represented
by our tenth consecutive quarter generating net revenue. The
Company's Financial Statements and Notes, as well as Management's
Discussion and Analysis ("MD&A") are filed on SEDAR
at www.sedarplus.ca.
This quarter reflects another period generating positive
earnings and Adjusted EBITDA1 for CanadaBis, despite a
26% decrease in gross revenue over the same period the prior year
due to increased competition in the market, and the resultant price
compression. In response, the Company has allocated capital to
innovation designed to remain ahead of competitors and to expand
the SKU offering by adding multiple new products for future
release. To support the Company's product enhancement initiatives,
we have adjusted our strategy to increase brand awareness and
capture market share through an extensive nation-wide campaign
designed to equip retailers with enhanced awareness of the various
SKUs, programs and educational value-adds to CanadaBis' wide
variety of high-quality, lower-cost products. While such
investments can have an impact on results in the immediate
quarters, reinvesting in the business is critical to support the
Company's top and bottom line over the longer-term.
Stigma Grow continues to re-formulate concentrate lines to meet
demands from current clients to maintain larger terpene and
cannabinoid profiles across the product offerings while also
earning repeat sales. With these ongoing improvements, coupled with
demand for our award-winning Infused Pre-rolls, Electric Dartz,
Live Rosin Vapes and High-CBD Cartridges, CanadaBis anticipates
continued positive performance in Fiscal 2024, while maintaining
prudent financial management.
"Building on momentum realized in Q1 2024, I am proud to report
that our second fiscal quarter represents another period of
positive net revenue, earnings and adjusted EBITDA, reflecting our
resilience despite a significant increase in competition and
meaningful price compression as cultivators and processors
reposition themselves in the market," said Travis McIntyre, CEO of CanadaBis. "Both in
fiscal Q2 and Q3 2024, we are directing investment to enhance our
product offering, while also launching a comprehensive nation-wide
retail-focused marketing campaign that leverages existing brand
awareness. Our goal is to increase the profile of established
brands while supporting the introduction of at least 17 exciting
new SKUs that we anticipate will increase sales in subsequent
quarters. With our unique capabilities and consumer-centric value
proposition, the Company has earned brand loyalty that positions us
well to drive continued shareholder value creation in an industry
rife with competition and continued regulatory challenges."
Q2 2024 HIGHLIGHTS
- Major Growth in Cultivation and Wholesale Segment – Net
revenue from the Cultivation and Wholesale segment for Q2 2024 was
$0.7 million compared to $0.03 million for the corresponding period in
2023, representing over 2000% growth. Several specialized SKU
launches in the provinces contributed to this increase, including
the Super Slim Cigarette Style Pre-roll and milled flower,
positioning CanadaBis in a niche category of providing high
quality, yet affordable, products. This new product is expected to
increase sales throughout fiscal 2024, along with new dry flower
brands and yet-to-be released SKUs. For the six months ended
January 31, 2024, net revenue in the
segment increased to $1.5 million
from $0.07 million in the
corresponding period of 2023.
- New Products Remain Critical to Continued Success - In
tandem with enhanced marketing efforts focused on increasing
awareness of the Dab Bods brand, the Company intends to introduce a
minimum of 17 new SKUs to the market through the coming quarters.
Leveraging the Company's existing brands and unique products, such
as our infused and non-infused Super Slim Cigarette Style
Pre-Rolls, the "Electric Dartz", affords a stable platform on which
to launch exciting new brands and SKUs.
- Continued Profitability - Adjusted EBITDA1
totaled approximately $0.5 million,
while net income totaled $0.11
million after tax in Q2 2024, representing the tenth
consecutive quarter of profitability.
- Cost Management Remains a Sharp Focus - The Company
continued to actively manage input expenses and inflationary
pressures through negotiations and economies of scale, securing
cost savings while increasing operational efficiencies and
expanding yields in cultivation and extraction. Cost management
plans remain in focus, along with initiatives designed to increase
efficiencies, improve cash flow and enhance liquidity.
QUARTERLY HIGHLIGHTS
|
Three months ended
January 31
|
|
2024
|
Gross
revenue
|
$7,071,336
|
Excise duty
|
2,762,572
|
Net revenues
|
$4,308,764
|
Cost of
sales
|
2,250,159
|
Gross profit
|
2,058,605
|
Net income and
comprehensive income
|
109,901
|
Per share (basic and
diluted)
|
-
|
Adjusted
EBITDA1
|
$564,609
|
OUTLOOK
With ongoing year-over-year profitability and cost controls
realized to date in Q2 2024, CanadaBis has set the stage to
continue delivering positive results by capitalizing on the budding
cultivation and wholesale segment, while reinvesting to refresh
extract brands and effectively navigate a rapidly evolving, and
highly competitive cannabis industry.
The Company has established several competitive advantages to
ensure long-term success, which will be leveraged in the ongoing
marketing campaign, including offering top-quality extracts derived
through our butane hydrocarbon (BHO) extraction process, first of a
kind Infused Pre-Rolls and Super Slim Cigarette Style Electric
Dartz Pre-Rolls. Investment in new formulations that can meet
demand and support the diversification of the Company's product
offerings increased in the current quarter, while rising demand
from Manitoba for both new and
existing products has broadened the market. The Company is pleased
to confirm that Dab Bod and High Priestess products continue to
attract greater market share reflecting the success of our ongoing
marketing efforts.
As a vertically integrated cannabis organization, the Company
brings unique insights and the ability to respond swiftly to
external factors that may impact selling prices, input costs or
shifting customer demands. With an unwavering commitment to
strategic capital management, the extensive CanadaBis portfolio
will represent a platform on which to support future growth. The
Company intends to allocate capital to further develop innovative
products that optimally align with consumer preferences, while
ensuring strong brand recognition in order to capture increased
market share.
The Company remains committed to shareholder value creation, by
actively pursuing growth opportunities; remaining agile to react
swiftly within a volatile cannabis market; and consistently
striving to improve quality and operational standards. CanadaBis
looks forward to sharing further updates on our continued progress
and success during the second half of 2024, and appreciates the
support of all shareholders, the Board of Directors and dedicated
employees.
ABOUT CANADABIS CAPITAL INC.
CanadaBis Capital Inc. (TSXV:CANB) is a vertically integrated
Canadian cannabis company focused on achieving large-scale growth,
from cultivation to retail, in the fast-emerging global cannabis
market. By targeting organic growth opportunities alongside the
right-fit partners, we remain focused on finding and capitalizing
on chances to grow, diversify and continue to lead our
industry.
Our integrated subsidiaries:
- Stigma Pharmaceuticals Inc. – 100% held
- 1998643 Alberta Ltd. (operating as "Stigma Grow") - 100%
held; www.stigmagrow.ca
- Full Spectrum Labs Ltd. (operating as "Stigma Roots") -
100% held
- 2103157 Alberta Ltd. (operating as "INDICAtive
Collection") -100% held; www.indicativecollection.ca
- Goldstream Cannabis Inc. - 95% held
ABOUT STIGMA GROW
Stigma Grow is a cutting-edge cannabis cultivation and
extraction company positioned advantageously to meet the unmet
market demands and stigmas within the legal cannabis industry head
on, with products designed to disturb the status quo and
dramatically shift the conversation surrounding Canada's legal cannabis industry.
CAUTIONARY STATEMENTS
Non-GAAP Measures
This news release contains the financial performance metric of
Adjusted EBITDA, a measure that is not recognized or defined under
IFRS (a "Non-GAAP Measure"). As a result, this data may not be
comparable to data presented by other cannabis companies. For an
explanation and reconciliation of Adjusted EBITDA to related
comparable financial information presented in the Financial
Statements prepared in accordance with IFRS, refer to the MD&A
for the three months ended October 31,
2023. The Company believes that Adjusted EBITDA is a useful
indicator of operational performance and is specifically used by
management to assess the financial and operational performance of
the Company.
Adjusted EBITDA is a measure of the Company's financial
performance. It is intended to provide a proxy for the Company's
operating cash flow and is widely used by industry analysts to
compare CanadaBis to its competitors and derive expectations of
future financial performance of the Company. Adjusted EBITDA
increases comparability between comparative companies by
eliminating variability resulting from differences in capital
structures, management decisions related to resource allocation,
and the impact of fair value adjustments on biological assets,
inventory, and financial instruments, which may be volatile on a
period-to-period basis. Adjusted EBTIDA is not a recognized,
defined, or standardized measure under IFRS. The Company calculates
Adjusted EBITDA as net income (loss) and comprehensive income
(loss) excluding changes in fair value of biological assets, change
in fair value of biological assets realized through inventory sold,
depreciation and amortization expense, share-based payments, and
finance costs.
Regarding Forward-Looking Information
This news release includes certain "forward-looking statements"
under applicable Canadian securities legislation. Forward-looking
statements include but are not limited to statements with respect
to our business and operations; timing of the Sundial products
coming to market; the demand and market for live-resin vape
cartridges, and our general business plans. Forward-looking
statements are necessarily based upon a number of assumptions
including: the ability of the Company's products to compete with
the pricing and product availability on the black-market; the
market demand for the Company's products; and assumptions
concerning the Company's competitive advantages. These assumptions,
while considered reasonable, are subject to known and unknown
risks, uncertainties, and other factors which may cause actual
results and future events to differ materially from those expressed
or implied by such forward-looking statements. Such factors
include, but are not limited to: compliance with extensive
government regulation, the general business, economic, competitive,
political and social uncertainties; ability to sustain or create a
demand for a product; requirement for further capital; delay or
failure to receive board, shareholder or regulatory approvals; the
results of operations and such other matters as set out in the
Company's continuous disclosure on SEDAR at www.sedar.com. There
can be no assurance that such statements will prove to be accurate,
as actual results and future events could differ materially from
those anticipated in such statements.
Accordingly, readers should not place undue reliance on
forward-looking statements. Investors are cautioned that
forward-looking information is not based on historical facts but
instead reflects management's expectations, estimates or
projections concerning future results or events based on the
opinions, assumptions and estimates of management considered
reasonable at the date the statements are made. Although we believe
that the expectations reflected in such forward-looking information
are reasonable, such information involves risks and uncertainties,
and undue reliance should not be placed on such information, as
unknown or unpredictable factors could have a material adverse
effect on our future results, performance or achievements.
Should one or more of these risks or uncertainties materialize,
or should assumptions underlying the forward-looking information
prove incorrect, actual results may vary materially from those
described herein as intended, planned, anticipated, believed,
estimated or expected. Although the Company has attempted to
identify important risks, uncertainties and factors which could
cause actual results to differ materially, there may be others that
cause results not to be as anticipated, estimated or intended. The
Company does not intend, and does not assume any obligation, to
update this forward-looking information except as otherwise
required by applicable law.
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
SOURCE CanadaBis Capital Inc.